Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ventripoint Diagnostics Ltd. Regulatory Filings 2021

Oct 1, 2021

45675_rns_2021-10-01_0fbbf25e-0899-4248-92d1-a3aecc9482d2.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

FORM 51-102F3 MATERIAL CHANGE REPORT

1. Name and Address of Company

Ventripoint Diagnostics Ltd. (the " Company ") 2 Sheppard Ave. E. Suite 605 Toronto, ON M2N 5Y7

2. Date of Material Change

September 27, 2021.

3. News Release

On September 27, 2021, a news release was issued and disseminated through the facilities of a recognized newswire service.

4. Summary of Material Change

The material change is fully described in the Company’s press release which is attached as Schedule “A” and is incorporated herein.

5. Full Description of Material Change

A description of the material change is contained under Item 4.

6. Reliance on subsection 7.1(2) of National Instrument 51-102

The report is not being filed in reliance on section 7.1(2) of National Instrument 51-102.

7. Omitted Information

No information has been omitted.

8. Executive Officer

The name of the executive officer of the Company who is knowledgeable about the material change and this report is:

Dr. George Adams, Chief Executive Officer Tel: (519) 803-6937 Email: [email protected]

9. Date of Report

September 28, 2021.

SCHEDULE “A”

PRESS RELEASE

==> picture [494 x 664] intentionally omitted <==

==> picture [498 x 396] intentionally omitted <==